Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis.
about
Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic ApproachesPathophysiology, staging and therapy of severe sepsis in baboon modelsTACTIC: Trans-Agency Consortium for Trauma-Induced CoagulopathyComplement: a key system for immune surveillance and homeostasisEscherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.The Baboon (Papio spp.) as a model of human Ebola virus infection.Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy.Crosstalk between the coagulation and complement systems in sepsis.Complement, thrombotic microangiopathy and disseminated intravascular coagulation.Complement in disease: a defence system turning offensiveNew milestones ahead in complement-targeted therapy.Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatinComplement depletion deteriorates clinical outcomes of severe abdominal sepsis: a conspirator of infection and coagulopathy in crime?Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency.Complement System Part I - Molecular Mechanisms of Activation and Regulation.Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin.Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filtersMolecular characterization of transcriptome-wide interactions between highly pathogenic porcine reproductive and respiratory syndrome virus and porcine alveolar macrophages in vivo.Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human bloodCompstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endotheliumNovel protein ADTRP regulates TFPI expression and function in human endothelial cells in normal conditions and in response to androgen.Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.Alternative Pathway Inhibition by Exogenous Factor H Fails to Attenuate Inflammation and Vascular Leakage in Experimental Pneumococcal Sepsis in Mice.Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humansInteractions between coagulation and complement--their role in inflammationComplement inhibition decreases early fibrogenic events in the lung of septic baboons.New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic propertiesComplement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.Progress and Trends in Complement TherapeuticsComplement in immune and inflammatory disorders: therapeutic interventions.Sphingosine 1-phosphate and its carrier apolipoprotein M in human sepsis and in Escherichia coli sepsis in baboons.The Effect of Esmolol on Tissue Perfusion and Clinical Prognosis of Patients with Severe Sepsis: A Prospective Cohort Study.Complement activation: an emerging player in the pathogenesis of cardiovascular diseaseAcute lung injury and fibrosis in a baboon model of Escherichia coli sepsis.Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention.
P2860
Q26797414-42498223-3268-4E1A-B803-8D902346A571Q27024559-943FABCF-B0A1-49CB-92B0-2302E44530C2Q28083939-3AD55207-8DC8-44C2-9C73-975996604673Q29615484-1240BE5D-247D-4734-9D06-8248912156ABQ33394010-DAEE40C9-56BF-4116-8B68-642C1A52CB9AQ33404644-5A202752-B88F-42F9-8278-56DEF1C9B9F5Q33408183-86045B2E-3222-4BBC-8686-FF53A7A91482Q33414814-6D3DBAE6-164B-470F-8A37-A5DD259C0244Q33420624-757C677E-2BAB-45E3-A83A-D09A2E631D79Q33432423-768EA1FB-7E94-42E1-A314-16C1153B1024Q33602320-BE66E099-D8AC-4C04-A243-F9DCB5D8E060Q34254555-F6A72C16-5E44-44FF-9AFE-F0BCEAE2AFC0Q34455129-FFC771CB-123B-40CF-BAC8-76D06B3F8510Q34459360-0FF8BE21-F4D0-4099-959D-A51155622AE3Q34481071-39664BB8-9CC4-41A4-9323-AD88C3F9EF11Q34704572-CA0F867F-5134-4D84-BE8D-DBBAB96FA688Q35109329-371C6EF1-40EA-4013-8356-68071C5D9717Q35164180-E5B65593-E4D8-472C-997D-F023FAF7B6A6Q35168206-0578F788-514E-4B4B-8C23-7C37F2C941A1Q35186384-0343EA31-179B-4F6E-A0C6-73A455F7A298Q35236103-BE13ED98-569F-4D04-A139-715784E91288Q35252156-01A39900-3435-4546-9C03-E9FCD08DF2E6Q35252177-ABED15AF-0B45-4B44-B03E-1DC4958D6063Q35485855-99B84070-5799-4779-BBC1-E9EEFF63B8A9Q35558208-63CE8027-6C69-4E2F-9452-F3E4EEA304C9Q35922386-33C5068F-1F54-4FB5-8DE3-E58FC863F581Q35987250-817A6541-EA0E-4021-8B83-0B6CC7ED127AQ36022738-4133C5CD-0976-4C05-9D12-AF42397356A4Q36232817-DD490340-DC79-4416-8381-E5D23FD34017Q36456593-2E1CCF2F-1448-448C-A12E-5DA04BD61BB8Q36460034-D92D7C1C-39B3-44EA-B400-28A29A5F6927Q36463266-01D63644-ADB8-4B48-B987-D30F929DAFCDQ36479278-AF5E5E2D-FBDC-479D-A681-EEBAF0E7A071Q36756854-9ABF6EF3-C574-48BD-8A8F-63F75B15E578Q36942346-5AFEEAFE-EDBF-4257-A282-F990D82B22E3Q37249832-94239FAF-3067-4A3D-B3A4-D03B4B61D328Q37288362-0D6A5CDA-948C-4F36-BEC4-C9BED3DE1F10Q37596157-4FAE504B-5AF9-43BF-8268-EE3B3CDCA2D0Q37670073-A0830916-D0EF-47AA-8CB9-8F206390BE5BQ37808230-F4FA407E-84FC-4678-997F-2C71A04D91ED
P2860
Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Complement inhibition decrease ...... el of Escherichia coli sepsis.
@ast
Complement inhibition decrease ...... el of Escherichia coli sepsis.
@en
type
label
Complement inhibition decrease ...... el of Escherichia coli sepsis.
@ast
Complement inhibition decrease ...... el of Escherichia coli sepsis.
@en
prefLabel
Complement inhibition decrease ...... el of Escherichia coli sepsis.
@ast
Complement inhibition decrease ...... el of Escherichia coli sepsis.
@en
P2093
P2860
P50
P1433
P1476
Complement inhibition decrease ...... el of Escherichia coli sepsis.
@en
P2093
Cristina Lupu
Fletcher B Taylor
Florea Lupu
Gary Kinasewitz
Georgia Sfyroera
Glenn Peer
Lacramioara Ivanciu
Paola Magotti
Robert Silasi-Mansat
P2860
P304
P356
10.1182/BLOOD-2010-02-269746
P407
P577
2010-05-13T00:00:00Z